References

Thane Wettig– Chief Commercial Officer at Fibrogen Inc.

“Robert is a deeply experienced marketing professional with expertise at the global and country level. Robert has successfully built and re-positioned multiple brands and led launches as the global marketing director for diabetes brands. He has a unique blend of strategic and operational skills which will enable him to engage in planning and execution. I highly recommend Robert as a marketing consultant”

Matt Beebe– Divisional Vice President/ General Manager at Abbott Nutrition

“Robert brings expertise in commercialization of brands in the US and Internationally. His unique skills in strategy development, Brand Management, Customer Insights, and tactical execution enables him to support Brand and Company success in many ways. He has taken these skills and developed the ability to design and implement training programs for teams. I have worked with Robert for many years in different assignments and he is one of the BEST, and a lot of fun to be around”

Tim McCort– Partner at Kickdrum strategy & creative

“I immensely enjoyed working with Robert. We faced many tough challenges together launching a new global diabetes therapy. In an under-resourced situation, Robert taught me how to create a plan out of what looked like chaos. Robert’s approach to business includes more than just understanding the objectives. He takes time to understand the people and the nuance of a situation, which makes him an effective leader. If you have a chance to work with Robert, I suggest you take it”

Gregg Talbert – Vice President, Global Head Personalized Health Care Partnering at Roche

“Robert is a multi-talented person who has added much value to many projects through his career. First, Roberts core talent and experience lies in the marketing field. In projects through his career. First, Roberts core talent and experience lies in the marketing field. In my experience with him, his commercial and product expertise has been resulted in great outcomes for patients and the company. Robert’s expertise extends beyond the commercial, as he is a great leader as well. I have had the opportunity to see him lead a broad international team through very complex issues which could not have been navigated without his talent. In addition, I have also seen the loyalty that his teams show toward him, which is a core element of a leader’s effectiveness. Finally, Robert is a great person to work with. His passion for the patient is infectious, and through him this passion extends broadly to the teams with which he works. I would personally look forward to working with Robert again, and I would highly recommend him to anyone seeking an expert commercial talent who has demonstrated strong leadership capabilities”

Publication References for Adrien

ACADEMIC RESEARCH

Manuscripts, papers

  • Sipos A, Czirjak L, Lorincz G, Szegedi Gy 1988. Studies on anti-granulocyte and anti-platelet antibodies in patients with systemic sclerosis. Scand J Rheumatology 17:43-50.
  • Sipos A, Csortos Cs, Sipka S, Gergely P, Sonkoly I, Szegedi Gy 1988. The antigen/receptor specificity of antigranulocyte antibodies in patients with SLE. Immunol Letters 19:329-334.
  • Pulford KAF, Sipos A, Cordell JL, Stross WP, Mason DY 1990. Distribution of the CD68 macrophage/myeloid associated antigen. International Immunology 2:973-980.

Book chapters

  • Sipos A, Lukacs K, Gyimesi E, Suranyi P, Pecze K, Szegedi Gy 1987. Comparison studies on 4 different leukaemic cell types with myeloid monoclonal antibodies. In: Leukocyte Typing III. Ed: McMichael AJ. pp 651-653. Oxford University Press.
  • Zeher M, Gyimesi E, Suranyi P, Sipos A, Szegedi Gy 1989. Activation antigens on the surface of peripheral blood lymphocytes (PBL) from patients with primary Sjogren’s syndrome. pp 489-491 In: Leukocyte typing: White Cell Differentiation Antigens. Ed:  Knapp W, pp 489-491. Oxford University Press.

Abstracts

  • Sipos A, Czirjak L, Szegedi Gy 1987. Studies on anti-granulocyte antibodies in patients with scleroderma (PSS). Eur J Clin Invest 27: A61.
  • Gyimesi E, Sipos A, Suranyi P, Sonkoly I, Zeher M, Szegedi Gy 1989. Analysis of myeloid antigen expression on peripheral blood granulocytes of patients with systemic lupus erythematosus.  Tissue Antigens (suppl) 33:214.
  • Zeher M, Gyimesi E, Suranyi P, Sipos A, Szegedi Gy 1989. Activation antigens on the surface of peripheral blood lymphocytes from patients with primary Sjogren’s syndrome.Tissue Antigens (suppl) 33:335.

PHARMACEUTICAL RESEARCH AND DEVELOPMENT

Manuscripts, papers

  • Chen P, Satterwhite JS, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005. Early changes in biochemical markers of bone formation predict bone mineral density response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970.
  • Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L-G, Gallagher JC, Pavo II, Wang J, Eriksen EF 2005. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrine Metabol 90:3970-3977.
  • Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH 2005.  Sustained non-vertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507-1513.
  • Chen P, Recker R, Resch H, Misurski D, Pavo I, Sipos A 2007. Association between changes in BMD and microarchitecture in postmenopausal women in osteoporosis treated with teriparatide in the fracture prevention trial. J Clin Densitometry 10 (2):200.
  • Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos A 2007. Increases in BMD Correlate with Improvements in Bone Microarchitecture with Teriparatide Treatment in Postmenopausal Women with Osteoporosis J Bone Miner Res 22 (8): 1173-1180.
  • Stepan JJ, Burr DB, Pavo I, Sipos A, Michalská D, Li J, Fahrleitner-Pammer A, Petto H, Westmore M, Michalsky D, Sato M, Dobnig H 2007. Low Bone Mineral Density is Associated with Bone Microdamage Accumulation in Postmenopausal Women. Bone 41 (3): 378-85.
  • Adami S, San Martin J, Munoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A 2008.  Effect Of Raloxifene After Recombinant Teriparatide [hPTH(1-34)] Treatment in Postmenopausal Women with Osteoporosis Osteoporos Int 19(1): 84-97.
  • Dobnig H, Stepan JJ, Burr DB, Li J, Michalska D, Sipos A, Petto H, Fahrleitner-Pammer A, Pavo I 2009. Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated with Alendronate J Bone Miner Res 24 (12):1998–2006.
  • Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalská D, Pavo I 2010. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 21(12):2027-36.
  • Goldstein SR, Bhattoa HP, Neven P, Cox DA, Dowsett SA, Alam J, Sipos A, Muram A 2012. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.  Menopause 19 (1):41-7.
  • Recknor CP, Recker RR, Benson CT, Robins DA, Chiang AY, Alam J, Hu L, Matsumoto T, Sowa H, Sloan JH, Konrad RG, Mitlak BH, Sipos AA. 2015.
  • The Effect of Discontinuing Treatment with Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women with Low Bone Mineral Density JBMR, DOI10.1002/jbmr.2489.

Abstracts

  • Dobnig H, Fahrleitner A, Ste-Marie L-G, Gallagher JC, Pavo I, Sipos A, Wang J, Eriksen EF. Early changes in biochemical markers of bone formation predict improvements in bone structure during teriparatide therapy. Endocrine Society Meeting, 2003. Philadelphia.
  • Stepan JJ, Burr DB, Pavo I, Sipos A, Michalska D, Li J, Petto H, Westmore M, Sato M, Dobnig H. Prevalent Fractures, Low Bone Mineral Density and Ageing are Associated with Greater Histomorphometric Indicators of Microdamage Accumulation in Postmenopausal Women.  ASBMR 2005. Nashville
  • Recker RR., Resch H, Chen P, Misurski DA, Pavo I., Sipos A. Relationship Between Teriparatide-Mediated Changes in BMD and Microarchitecture in Postmenopausal Women with Osteoporosis. ECCEO 2006, Vienna and IOF 2006, Toronto
  • Michalská D, Glüer CC, Stepan JJ, Pavo I, Sipos A, Petto H, Burr DB, Sato M, Neuwirth J, Dobnig H. Correlations between static trabecular parameters measured by qualitative computer tomography or histomorphometry in postmenopausal women with osteoporosis. ECTS 2006.  Prague
  • Stepan JJ, Burr DB, Pavo I, Sipos A, Li J, Michalska D, Petto H, Dobnig H. The correlations between serum markers and dynamic histomorphometry are more pronounced in alendronate-treated than naive patients with postmenopausal osteoporosis. ASBMR 2006.
  • Adami A, Munoz-Torres M, Econs M, Sipos A, Xie L, Dalsky G, McClung M, Felsenberg D, Brown J, Brandi M, San Martin J. Effect of Raloxifene After Teriparatide (rhPTH(1-34) Treatment in Postmenopausal Women with Osteoporosis. Osteoporos Int. 2006;17(Supp 2): S137.
  • Li J, Burr DB, Stepan JJ, Dobnig H, Fahrleitner-Pammer A, Sipos A, Mullarney T, Westmore M, Sato M, Pavo I. Teriparatide Improves Bone Microarchitecture in Postmenopausal Women Previously Treated with Alendronate ASBMR 2007.
  • Dobnig H, Stepan JJ, Burr DB, Fahrleitner-Pammer A, Li J, Sipos A, Mullarney T, Sato M, Pavo I: Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated with Alendronate. ASBMR 2007.
  • Chen P, Recker RR, Resch H, Misurski DA, Pavo I, Sipos A. Association between changes in BMD and microarchitecture in postmenopausal women with posteoporosis treated with teriparatide in the Fracture Prevention Trial. ISCD 2007.
  • Pavo I, Stepan JJ, Li J, Michalska D, Sipos A, Petto H, Burr DB, Dobnig H,.The microdamage accumulation is more frequent in patients with impaired trabecular bone microstructure. ECTS 2007.
  • Sipos A, See K, Rohe M, Mitlak BH.  Antibody response to teriparatide follow up. Annual European Congress of Rheumatology (EULAR) 2007. Abstract number: 2743.
  • Li J, Burr DB, Stepan JJ, Fahrleitner-Pammer A, Sipos A, Mullarney T, Westmore M, Dobnig H, Sato M, Pavo I. Teriparatide improves bone michoarchitecture in postmenopausal women previously treated with alendronate. J Bone Miner Res. 2007;22:S1–S28.
  • Stepan JJ, Dobnig H, Burr DB, Li J, Ma YL, Sipos A, Petto H, Pavo I. Histomorphometric Changes by Teriparatide in Alendronate Pre-treated Women with Osteoporosis. ASBMR 2008.
  • Benson Ch, Robins D, Recker R, Alam J, Chiang AY, Mitlak B, Sipos A, Hu L. Effect of blosozumab on bone mineral density: Results of a Phase 2 study of postmenopausal women with low bone mineral density. Bone Abstracts (2013) Vol 1 OC5.3| DOI: 10.1530/boneabs.01.OC5.3
  • Keaveny TM, Myers SL, AY Chiang, Alam J, Robins DA, Krege JH, Sipos AA, Mitlak BH, CT Benson Effect of Blosozumab on Estrimated Spine and Hip Strength in Postmenopausal Women with Low Bone Mineral Density:Finite Element Analysis of a Phase 2 Dosing Study. ASBMR 2013 (1025).
  • C Benson, AY Chiang, L Hu, A Jahangir, BH Mitlak, R Recker, DA Robins, H Sowa, AA Sipos Effect of Blosozumab on Bone Mineral Density: 52-Week Follow-up of a Phase 2 Study of Postmenopausal Women with Low Bone Mineral Density. ASBMR 2014